Trial Profile

An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 May 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Dec 2024.
06 May 2024 According to an ArsenalBio media release, data from this study will be highlighted at the American Society of Gene + Cell Therapy (ASGCT) annual meeting
05 Jan 2023 According to an ArsenalBio media release, an update inclusive of information about the clinical trial will be provided during the company's upcoming presentation at the 41st Annual J.P. Morgan Healthcare Conference.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com